IP Library Granted Patent US 10,669,596
Granted Patent B2
US 10,669,596 · App. 15/564,752 · Granted Jun 2, 2020

Methods for inducing cell division of postmitotic cells

Inventors: Tamer M. A. Mohamed (San Francisco, CA); Deepak Srivastava (San Francisco, CA)
Assignee: The J. David Gladstone Institutes, a testamentary trust established under the Will of J. David Gladstone
C12Y207/11022A61K35/30A61K35/34A61K35/36A61K35/39A61K38/1709A61K38/45A61P9/10A61K35/00A61K2300/00C12N2310/111
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,669,596
App. No.
15/564,752
Granted
Jun 2, 2020
Kind
B2
Abstract

The present disclosure provides methods for inducing cell cycle reentry of postmitotic cell. The present disclosure further provides cells and compositions for treating diseases, such as cardiovascular diseases, neural disorders, hearing loss, and diabetes.

Claims (9)

1. A method of inducing proliferation and/or cell cycle reentry of an adult postmitotic cell, the method comprising contacting the adult postmitotic cell with an effective amount of a composition comprising cyclin-dependent kinase-1 (CDK1), cyclinB, CDK4, and cyclinD, or equivalents of each thereof, thereby inducing proliferation and/or cell cycle reentry of the adult postmitotic cell.

2. The method of claim 1 , further comprising contacting the cell with an effective amount of a CDK activator, a transforming growth factor β inhibitor, or combinations thereof.

3. The method of claim 2 , wherein the CDK activator is a CDK1 activator.

4. The method of claim 1 , wherein the adult postmitotic cell is selected from the group consisting of a cardiomyocyte, a neural cell, a pancreatic cell, a hair cell, and a skeletal muscle cell.

5. The method of claim 1 , wherein the cyclin-dependent kinase-1 (CDK1), cyclinB, CDK4, and cyclinD encoded by at least one heterologous nucleic acid.

6. The method of claim 5 , wherein the at least one nucleic acid is a modified mRNA.

7. The method of claim 6 , wherein the at least one nucleic acid is constitutively expressed.

8. The method of claim 1 , wherein the cyclinB is cyclinB1 (CCNB1), and/or the cyclinD is cyclinD1 (CCND1).

9. The method of claim 1 , wherein the CDK1 and/or CDK4 is constitutively expressed.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 6, 2017
From: MOHAMED, TAMER M.A.; SRIVASTAVA, DEEPAK
To: THE J. DAVID GLADSTONE INSTITUTES, A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J. DAVID GLADSTONE
Reel/Frame 043802/0696 →
Continuity (3)
Provisional Application 62151321 · Apr 22, 2015
Provisional Application 62144244 · Apr 7, 2015
Related Publication 20180112282A1 · Apr 26, 2018
Cited By (1)
US 12,661,384